Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer

PURPOSE: The aim of our study was to evaluate the efficacy and safety of docetaxel plus ramucirumab with primary prophylactic pegylated (PEG)-granulocyte-colony stimulating factor (G-CSF) for pretreated non-small cell lung cancer (NSCLC). RESULTS: Sixty-one pretreated NSCLC patients underwent doceta...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Hata, Akito, Harada, Daijiro, Okuda, Chiyuki, Kaji, Reiko, Masuda, Yoshio, Takechi, Yoshika, Kozuki, Toshiyuki, Nogami, Naoyuki, Katakami, Nobuyuki
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2018
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021251/
https://ncbi.nlm.nih.gov/pubmed/29963237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25578
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы